Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 11/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926809 | 0.87 | NOX1 (0.44) | BCHEACHENOX1MAPTSMN1; SMN2 | |
| SCHEMBL1828807 | 0.84 | BCHE (0.37) | BCHEACHEMAPTKMT2AGAA | |
| SCHEMBL18906407 | 0.70 | BCHE (0.63) | BCHEMAPTMEN1KMT2AHPGD | |
| SCHEMBL396463 | 0.69 | BCHE (0.61) | BCHEACHENOX1MAPTSMN1; SMN2 | |
| SCHEMBL244827 | 0.67 | MAPK1 (0.62) | BCHEACHEMAPTSNCAMEN1 | |
| SCHEMBL29384821 | 0.67 | MAPK1 (0.62) | BCHEACHEMAPTSNCAMEN1 | |
| SCHEMBL17356853 | 0.67 | BCHE (0.41) | BCHEACHENOX1MAPTSMN1; SMN2 | |
| SCHEMBL17356860 | 0.66 | BCHE (0.67) | BCHEMAPTMEN1KMT2AHPGD | |
| SCHEMBL1207990 | 0.65 | NOX1 (0.41) | BCHEACHENOX1MAPTSNCA | |
| SCHEMBL17356855 | 0.64 | BCHE (0.66) | BCHEACHENOX1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020123150-A1 | Method | COLGATE-PALMOLIVE COMPANY | 2002-09-05 | — | — | US | claimed |
| WO-2002051362-A2 | METHOD | COLGATE-PALMOLIVE COMPANY (US) | 2002-07-04 | — | — | WO | claimed |
| US-5223404-A | Chromogen, oxidase, compound which releases rate enhancer in presence of peptidase | SUNSTAR KABUSHIKI KAISHA (JP) | 1993-06-29 | — | — | US | claimed |
| US-12264356-B2 | Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor | NIHON UNIVERSITY (JP) | 2025-04-01 | — | — | US | disclosed |
| EP-3461907-B1 | MEASUREMENT OF GLYCOPROTEIN | ARKRAY INC (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-10989714-B2 | Measurement of glycoprotein | ARKRAY, INC. (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200347458-A1 | METHOD FOR DETERMINING SENSITIVITY TO SGLT2 INHIBITOR AND SENSITIVITY MARKER FOR SGLT2 INHIBITOR | NIHON UNIVERSITY (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20190137502-A1 | Measurement of Glycoprotein | ARKRAY, INC. (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-3461907-A1 | MEASUREMENT OF GLYCOPROTEIN | ARKRAY, Inc. (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-2319937-B1 | BLOOD COMPONENT MEASUREMENT METHOD UTILIZING HEMOLYZED WHOLE BLOOD, AND KIT FOR THE METHOD | NIPPON KAYAKU KK (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-8999124-B2 | Detection device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-04-07 | — | — | US | disclosed |
| US-5426033-A | Accurate quantitative analysis | KYOWA MEDEX CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0608795-A1 | Method for enzymatic determination of substrate after enzymatically removing galactose | Kyowa Medex Co. Ltd. (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-5334507-A | Pyruvate kinase, glycerol kinase, glycerol-3-phosphate oxidase, peroxidase, reduced chromogen, adenosine diphosphate, phosphoenolpyruvic acid | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1994-08-02 | — | — | US | disclosed |
| EP-0533183-A2 | Composition for the measurement of potassium ion concentration | TOYO BOSEKI KABUSHIKI KAISHA Trading under the name of Toyobo Co., Ltd. (JP) | 1993-03-24 | — | — | EP | disclosed |
| EP-0174371-B1 | TRIPHENYLMETHANE DERIVATIVES AND METHOD FOR DETERMINING OXIDATIVE SUBSTANCES USING THEM AS COLOR-FORMING COMPONENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4778753-A | IN PRESCENCE OF URICASE, METAL CHELATE AND ANIONIC SURFACTANT; WITHOUT COLORING INTERFERENCE | WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4673635-A | Triphenyl methane derivatives and method of quantitatively measuring an oxidative substance | WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) | 1987-06-16 | — | — | US | disclosed |
| US-4613465-A | HYDROGEN PEROXIDE, BODY FLUIDS, ENZYMES | WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) | 1986-09-23 | — | — | US | disclosed |
| EP-0174371-A1 | TRIPHENYLMETHANE DERIVATIVES AND METHOD FOR DETERMINING OXIDATIVE SUBSTANCES USING THEM AS COLOR-FORMING COMPONENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10989714-B2 | Measurement of glycoprotein | ENGASE, UGGT1, ST6GAL1 | BCHE 703/4885ACHE 1316/4885CREBBP 4043/4885 |
| US-20190137502-A1 | Measurement of Glycoprotein | ENGASE, UGGT1, ST6GAL1 | BCHE 703/4885ACHE 1316/4885CREBBP 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.